Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405319 | 0.90 | L3MBTL1 (0.39) | L3MBTL1GAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3024254 | 0.86 | USP2 (0.43) | TSHRALDH1A1CYP2C19 | |
| SCHEMBL15121872 | 0.85 | GAA (0.38) | L3MBTL1GAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL403218 | 0.84 | GAA (0.38) | L3MBTL1GAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL403472 | 0.83 | L3MBTL1 (0.43) | L3MBTL1GAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3016967 | 0.81 | USP2 (0.31) | — | |
| SCHEMBL3026628 | 0.81 | USP2 (0.41) | ALDH1A1SMN1; SMN2ATMRECQLPDE4B | |
| SCHEMBL9721852 | 0.79 | L3MBTL1 (0.47) | L3MBTL1GAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL2828216 | 0.76 | NR1H2 (0.39) | ALDH1A1SMN1; SMN2RECQLPDE4BMAPT | |
| SCHEMBL959849 | 0.72 | SMN1; SMN2 (0.49) | SMN1; SMN2HTTPDE4BCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-25 | — | — | US | disclosed |
| EP-4146625-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2023-03-15 | — | — | EP | disclosed |
| CN-115515933-A | Translumenally acting N- (piperidin-4-yl) benzamide derivatives | 武田药品工业株式会社 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021225968-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021225968-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-11 | — | — | WO | disclosed |
| EP-1853586-B1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130150366-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA, INTELLECTUAL PROPERTY (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8399489-B2 | Antibacterial piperdine derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-5674868-A | ADMINISTERING TO TREAT DISORDERS SUCH AS ANXIETY, PSYCHOSIS, DEPRESSION, SCHIZOPHRENIA, DURG ABUSE, MIGRAINE, EMESIS AND IRRITABLE BOWEL SYNDROME | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-10-07 | — | — | US | disclosed |
| EP-0669919-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012494-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-06-09 | — | — | WO | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| EP-0121972-B1 | N-ARYL-ALPHA-AMINO-CARBOXAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-24 | — | — | EP | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0121972-A2 | N-aryl-alpha-amino-carboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-17 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150366-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, CFTR | L3MBTL1 3998/4885GAA 154/4885TSHR 4034/4885 |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | HTR4, HTR1A, HTR1D | L3MBTL1 3929/4885GAA 774/4885TSHR 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.